1:15pm - 2:15pm Monday, March 9

Location & Room

Orlando - Orange County Convention Center
W307A
Additional Registration
Extra Fee
As the use of wearables, omics, and geolocators are increasingly used in clinical trials, the amount of data is growing exponentially. As a result, more than 60% of pharmaceutical executives are planning to invest in blockchain technologies to foster innovation, and leverage these increasingly large data sets. Blockchain, coupled with artificial intelligence, is helping the industry explore data nuances as well as automating manual data tasks.   As examples, 10 large pharmaceutical companies are collaborating using a blockchain system called Melloddy (Machine Learning Ledger Orchestration for Drug Discovery). By training algorithms using each other's data, the goal is to accelerate and reduce the cost of drug development without revealing commercial secrets. A decentralized blockchain data mgmt system offers transparency for near real-time access across disparate systems for patient safety. Blockchain access controls ensure security where stakeholders can only access authorized information. The audit trail increases trust in data integrity and efficiency in regulatory reporting.  In this presentation, we will share how life science companies are currently transacting data using blockchain technologies. We will discuss features of federated learning to advance drug discovery. We will also share examples of blockchain data mgmt solutions that have demonstrated efficiencies within clinical trials. We will describe how to evaluate evidence about blockchain to maximize value.
Speakers: 
Chief Scientific Officer,
Flowmetric Life Sciences
Research Compliance Manager,
Denver Health
Continuing Education Credits: 
CAHIMS
1.00
CME
1.00
CNE
1.00
CPHIMS
1.00